Source: Barrett, et al JAMA Surgery, September 17, 2025 Researchers correlated insurance claims data and electronic medical records in a system that owns both an insurance plan (Highmark) and a provider system (Allegheny Health), and compared total medical expense for over 30,000 individuals who had either metabolic and bariatric surgery (sleeve gastrectomy) or were treated with GLP-1 medications between 2018 and 2023
Thus, GLP-1 RAs, rather than GIP RAs, were initially identified as a key therapeutic target
Dietary strategies that complement semaglutide's mechanism include consuming smaller, more frequent meals to accommodate delayed gastric emptying and reduced stomach capacity
and An outside, existential chance you win patent/IP disputes over Big Pharma to continue offering slightly different GLP-1s to consumers long-term (or some sort of other sustainable workaround)
A plotter would have shown all of this in advance
It counteracts muscle atrophy and promotes full functional recovery, as evidenced by improved biomechanical and functional assessments in treated rats